ABBV-619
Unknown / undisclosed
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
No clinical trials on ClinicalTrials.gov
No clinical trial of this drug is registered on ClinicalTrials.gov, so there is nothing to grade. Studies run outside that registry are not tracked here.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.
No registered studies found. Not yet ingested, or none registered.
Competitive landscape
Other CD19 drugs
Inebilizumab, obecabtagene autoleucel, Tafasitamab, budoprutug, cemacabtagene ansegedleucel and 11 more. Compare all 17 CD19 drugs
This mechanism is crowded: 18 other tracked programmes target it.
This drug's own stage for Rheumatoid Arthritis: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| ABBV-619: this drug | Stage not on record | Undisclosed | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Abatacept (Orencia) | Approved | Protein / enzyme therapeutic | CD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cells | Reliable signal | NCT00048568: Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169 (Day 169): ABA + MTX DB 288/424 (67.9%) vs MTX + Placebo DB 85/214 (39.7%) NCT00048581: Double-blind Period (DB); Number of Participants With American College of Rheumatology (ACR) 20 Response at Day 169 (Day 169): Abatacept (ABA) 129/256 (50.4%) vs Placebo (PLA) 26/133 (19.5%) | |
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | NCT00195702: Primary 1, ACR20 at week 24: 63% (40 mg every other week) and 61% (20 mg weekly) vs 30% placebo, all with methotrexate (P<=0.001 for each), met. Primary 2, change in modified total Sharp score at week 52: 0.1 and 0.8 vs 2.7 (P<=0.001 for each), met. Primary 3, change in HAQ disability index at week 52: -0.59 and -0.61 vs -0.25 (P<=0.001 for each), met. | |
| Adalimumab-Aacf (Idacio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aaty (Yuflyma) | Approved | Monoclonal antibody | TNF-alpha | Partial signal | NCT03789292: ACR20 response at week 24, CT-P17 vs EU-adalimumab (ITT): 82.7% (268/324) in both groups; treatment difference 95% CI -5.94 to 5.94 (margin -15 to 15%) and 90% CI -4.98 to 4.98 (margin -12 to 15%), both within the predefined equivalence margins (Kay 2021, Arthritis Res Ther). | |
| Adalimumab-Adaz (Hyrimoz) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | No reviewed efficacy summary in this indication | |
| Adalimumab-Afzb (Abrilada) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | NCT02480153: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1 (Week 12): Period 1: PF-06410293 68.35% vs Period 1: Adalimumab-EU 71.33% | |
| Adalimumab-Aqvh (Yusimry) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Atto (Amjevita) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | Featured results are non-efficacy only in this race | |
| Adalimumab-Bwwd (Hadlima) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Fkjp (Hulio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Ryvk (Simlandi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Anakinra | Approved | Protein / enzyme therapeutic | Interleukin-1 Receptor Antagonist | Weak signal | No reviewed efficacy summary in this indication | |
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | Reliable signal | NCT02265705: ACR20 response at Week 12 (primary endpoint, 290 randomized, 145 per arm): 58.6% baricitinib 4mg vs 28.3% placebo (OR 4.1, 95% CI 2.5-6.9; p=0.001) NCT01710358: ACR20 response at Week 12 (primary endpoint): 70% baricitinib 4mg vs 40% placebo (P<0.001) | |
| BAT1806 (Tofidence) | Approved | Monoclonal antibody | IL-6 receptor | Partial signal | NCT03830203: ACR20 response rate at week 24: 67.9% reference tocilizumab vs 69.9% BAT1806/BIIB800; treatment difference 1.9% (90% CI -4.0 to 7.9), within predefined equivalence margins | |
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | Weak signal | Featured results are non-efficacy only in this race | |
| CT-P47 (tocilizumab) (Avtozma) | Approved | Monoclonal antibody | IL-6R antagonist | Reliable signal | NCT05489224: Mean Change From Baseline in Disease Activity Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) at Week 24 (Week 24): CT-P47 -3.77 units on a scale (Standard Error 0.12) vs RoActemra -3.67 units on a scale (Standard Error 0.118) NCT05725434: 12-week, single-arm, open-label Phase 3 usability study: Post-Self-Injection Assessment Questionnaire (POST-SIAQ) domain scores at Week 2 exceeded 8/10 for all domains except self-confidence (7.11) and satisfaction with self-injection (7.98); the study is reported to have met its primary usability endpoint, with no autoinjector malfunctions and no new safety signals. | |
| Etanercept (Enbrel) | Approved | Protein / enzyme therapeutic | TNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha) | Partial signal | NCT03780959: Percentage of Participants With Disease Flare in Part 2 (End of part 1 (day 90) and months 4 to 7): Part 2: Etanercept 0.4 mg/kg 28% vs Part 2: Placebo 81% | |
| Golimumab (Simponi) | Approved | Monoclonal antibody | TNF-alpha | Partial signal | NCT00264550: Co-primary 1, ACR20 response at week 14 vs placebo plus methotrexate (44/133, 33.1%): combined golimumab plus methotrexate 99/178 (55.6%), p<0.001, the prespecified primary test, met; golimumab 50 mg plus methotrexate 49/89 (55.1%), p=0.001; golimumab 100 mg plus methotrexate 50/89 (56.2%), p<0.001. Co-primary 2, median HAQ improvement at week 24 vs placebo plus methotrexate (0.125): combined golimumab plus methotrexate 0.4375, p<0.001, met; 50 mg plus methotrexate 0.375, p<0.001; 100 mg plus methotrexate 0.500, p<0.001. Golimumab 100 mg alone vs placebo plus methotrexate (for ACR20, tested only after a positive primary test): ACR20 59/133 (44.4%), p=0.059; HAQ 0.125, p=0.240; not significant. NCT00264537: ACR50 response at Week 24: placebo+MTX 47/160 vs combined golimumab+MTX (50mg or 100mg)+MTX 122/318; CMH p=0.053. Individually: golimumab 50mg+MTX 64/159 vs placebo+MTX 47/160, p=0.042; golimumab 100mg+MTX 58/159 vs placebo+MTX, p=0.177. | |
| Hydroxychloroquine | Approved | Small molecule | Autophagy/lysosomal acidification | not yet graded | No reviewed efficacy summary in this indication | |
| Inebilizumab | Approved(overall) | Monoclonal antibody | CD19 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Infliximab (Remicade) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | No reviewed efficacy summary in this indication | |
| Infliximab-Abda (Renflexis) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Axxq (Avsola) | Approved | Monoclonal antibody | TNF-alpha | Partial signal | Featured results are non-efficacy only in this race | |
| Infliximab-Dyyb (Inflectra) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | Featured results are pharmacokinetic only in this race | |
| Infliximab-Qbtx (Ixifi) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | NCT02222493: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1 (Week 14): Period 1: PF-06438179 198/324 (61.1%) vs Period 1: Infliximab-EU Remicade (INX) 207/326 (63.5%) | |
| Methotrexate | Approved | Small molecule | Dihydrofolate reductase (DHFR), Folate Analog Metabolic Inhibitor | Partial signal | NCT01185301: DAS28(CRP) < 3.2 at week 26 with adalimumab plus methotrexate 2.5, 5, 10 or 20 mg/week: 42.9%, 44.0%, 56.6% and 60.2% (n=98 to 100 per arm); statistically significant increasing trend with dose (Burmester et al., Ann Rheum Dis 2015). | |
| Methylprednisolone | Approved | Small molecule | Glucocorticoid receptor agonist | not yet graded | No reviewed efficacy summary in this indication | |
| Obecabtagene Autoleucel (Aucatzyl) | Approved(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | Partial signal | Featured results are pharmacokinetic only in this race | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Rituximab (Rituxan) | Approved | Monoclonal antibody | CD20, CD20-directed Cytolytic Antibody | Reliable signal | NCT00299130: Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Rituximab 2 x 0.5 g + MTX 54.5% | Rituximab 2 x 1.0 g + MTX 50.6% vs Placebo + MTX 23.3% NCT00468546: ACR20 response at week 24: 51.3% (153/298) with rituximab + methotrexate vs 17.9% (36/201) with placebo + methotrexate. | |
| Rituximab-Abbs (Truxima) | Approved | Monoclonal antibody | CD20 | Reliable signal | NCT02149121: Primary efficacy: DAS28-CRP change from baseline -2.11 with CT-P10 vs -2.10 with reference products; treatment difference -0.01 (90% CI -0.22 to 0.20), with an equivalence margin of ±0.50. Primary PK AUC0-last ratio: 97.07% (CT-P10/Rituxan; 90% CI 88.08% to 106.99%) and 94.18% (CT-P10/MabThera; 90% CI 85.40% to 103.86%). | |
| Sarilumab | Approved | Monoclonal antibody | IL-6 receptor | Reliable signal | NCT02332590: DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 (Baseline, Week 24): Sarilumab 200 mg/Sarilumab 200 mg -3.28 units on a scale (Standard Error 0.105) vs Adalimumab 40 mg/Sarilumab 200 mg -2.2 units on a scale (Standard Error 0.106) NCT01061736: Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline to Week 12): Part A: SAR 100 mg qw 62% | Part A: SAR 150 mg qw 72% | Part A: SAR 100 mg q2w 49% | Part A: SAR 150 mg q2w 66.7% | Part A: SAR 200 mg q2w 65.4% vs Part A: Placebo qw 46.2% | |
| Sulfasalazine | Approved | Small molecule | Aminosalicylate | not yet graded | No reviewed efficacy summary in this indication | |
| Tafasitamab | Approved(overall) | Monoclonal antibody | CD19 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Tocilizumab (Actemra / RoActemra) | Approved | Monoclonal antibody | IL-6 receptor | Reliable signal | NCT03155347: ACR20 response at Week 24: tocilizumab+methotrexate 52.9% (72/136) vs methotrexate alone 25.0% (17/68), difference 27.9pp (95% CI 14.7-41.2), P<.001; tocilizumab monotherapy 50.0% (68/136) vs methotrexate alone 25.0%, difference 25.0pp (95% CI 11.7-38.3), P<.001 NCT01232569: Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24 (Baseline to Week 24): Tocilizumab 162 mg sc 60.9% (95% CI 56.3 to 65.4) vs Placebo sc 31.5% (95% CI 25.4 to 37.7) | |
| Tofacitinib (Xeljanz) | Approved | Small molecule | JAK, JAK1/JAK3 | Weak signal | Featured results are non-efficacy only in this race | |
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | Reliable signal | NCT03086343: Change from baseline DAS28-CRP at week 12: -2.52 (95% CI -2.66 to -2.37) upadacitinib vs -2.00 (95% CI -2.14 to -1.85) abatacept; upadacitinib met primary non-inferiority and key secondary superiority endpoints. NCT02706873: Co-primary endpoints: ACR50 at Week 12 -- upadacitinib 15mg 52% (95% CI 47-58), 30mg 56% (95% CI 51-62), MTX 28% (95% CI 23-33), P<0.001 for both doses vs MTX. DAS28-CRP<2.6 at Week 24 -- upadacitinib 15mg 48% (95% CI 43-54), 30mg 50% (95% CI 45-56), MTX 19% (95% CI 14-23), P<0.001 for both doses vs MTX | |
| Acellbia | Phase 3 | Monoclonal antibody | CD20 | Reliable signal | NCT02744196: ACR20 response at Week 24 (ALTERRA trial, N=159): Acellbia+MTX 65.7% vs Placebo+MTX 29.4% (p<0.0001); difference 36.3% (95% CI 19.27-53.28%) | |
| Filgotinib (Jyseleca) | Phase 3 | Small molecule | JAK, JAK1 | Reliable signal | NCT02889796: ACR20 at week 12 (primary endpoint): FIL200 76.6% vs placebo 49.9% (difference 26.7%, 95% CI 20.6-32.8, p<0.001); FIL100 69.8% vs placebo 49.9% (difference 19.9%, 95% CI 13.6-26.2, p<0.001) NCT02873936: ACR20 response at Week 12: filgotinib 200mg 66.0%, filgotinib 100mg 57.5%, placebo 31.1%; difference vs placebo 34.9% (95% CI 23.5-46.3) and 26.4% (95% CI 15.0-37.9) respectively, both P<.001 | |
| HLX01 (Hanlikang) | Phase 3 | Monoclonal antibody | CD20 | Reliable signal | No reviewed efficacy summary in this indication | |
| Iguratimod | Phase 3 | — | NF-kB | Partial signal | NCT00965757: ACR20 response at week 24: iguratimod plus methotrexate 69.5% vs placebo plus methotrexate 30.7% (P < 0.001), n=164 vs 88 (Ishiguro et al., Mod Rheumatol 2013). | |
| Levilimab (Ilsira) | Phase 3 | Monoclonal antibody | IL-6 receptor | Reliable signal | NCT04227366: ACR20 response at week 12: 68.6% (levilimab + methotrexate) vs 38.5% (placebo + methotrexate). | |
| Telitacicept | Phase 3 | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication | |
| Zemprocitinib | Phase 3 | Small molecule | JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| Afimkibart | Phase 2 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| AZD1163 | Phase 2 | Biologic (subtype unspecified) | PAD2 and PAD4 (peptidyl arginine deiminase 2/4) | not yet graded | No reviewed efficacy summary in this indication | |
| Blinatumomab | Phase 2 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Budoprutug | Phase 2(overall) | Monoclonal antibody | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Cemacabtagene Ansegedleucel | Phase 2(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| CKD-506 | Phase 2 | Small molecule | HDAC6 (Histone deacetylase 6) | Partial signal | NCT04204603: Primary endpoint, change from baseline in DAS28(CRP) at week 12 (full analysis set, n=121): placebo -1.2, CKD-506 200 mg -1.0, 400 mg -1.3, 600 mg -1.2; pre-specified dose-response trend test p > 0.5 (EudraCT 2018-001377-24 posted results). missed | |
| Denosumab (Prolia) | Phase 2 | Monoclonal antibody | RANKL | Partial signal | NCT03239080: Erosion healing at 24 months: 20% (denosumab) vs 6% (placebo), p=0.045. NCT00095498: Primary endpoint (change from baseline in MRI erosion score at 6 months): denosumab 60 mg +0.13 (P=0.118, not significant) vs denosumab 180 mg +0.06 (P=0.007, significant) vs placebo +1.75. Modified Sharp erosion score: 180 mg significant vs placebo at 6 months (P=0.019); both 60 mg (P=0.012) and 180 mg (P=0.007) significant vs placebo at 12 months. | |
| FT819 | Phase 2(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Imeroprubart | Phase 2 | Monoclonal antibody | FcRn | not yet graded | No reviewed efficacy summary in this indication | |
| JAB-8263 | Phase 2 | Small molecule | BET bromodomain proteins (e.g. BRD4) | not yet graded | No reviewed efficacy summary in this indication | |
| Lutikizumab | Phase 2 | Multispecific antibody | IL-1α/IL-1β (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| MK-8690 | Phase 2 | Monoclonal antibody | CD30 ligand (CD30L / CD153) | not yet graded | No reviewed efficacy summary in this indication | |
| Natrunix | Phase 2 | Monoclonal antibody | IL-1 alpha | Partial signal | No reviewed efficacy summary in this indication | |
| Rapcabtagene Autoleucel | Phase 2(overall) | Undisclosed | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ravagalimab | Phase 2 | Monoclonal antibody | CD40 | not yet graded | No reviewed efficacy summary in this indication | |
| Rosnilimab | Phase 2 | Monoclonal antibody | PD-1 (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-3045 | Phase 2 | Undisclosed | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD0120 | Phase 1/2 | Cell therapy | BCMA / CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Beijing Biotech Anti-CD19 CAR-T | Phase 1/2(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Zugocabtagene Geleucel | Phase 1/2(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ABBV-319 | Phase 1 | Antibody–drug conjugate | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-519 | Phase 1 | — | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD5492 | Phase 1 | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD6912 | Phase 1 | RNA / oligonucleotide | Complement Factor B (CFB) mRNA | Weak signal | No reviewed efficacy summary in this indication | |
| Azercabtagene Zapreleucel | Phase 1(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| BMS-986454 | Phase 1 | — | PAD4 (peptidylarginine deiminase 4) | not yet graded | No reviewed efficacy summary in this indication | |
| IC19 CAR-T | Phase 1(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| UTAA09 | Phase 1(overall) | Cell therapy | CD19 | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| ZM001 | Phase 1(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| FT522 | —(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| GLPG5101 | Discontinued | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Vispacabtagene Regedleucel | Discontinued | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Large race: only the 78 furthest-along competitors are listed; 21 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
No upcoming readouts on record for this asset.